Results 121 to 130 of about 4,801,266 (265)
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq +8 more
wiley +1 more source
Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers [PDF]
Copolymers of N-(2-hydroxypropyl)methacrylamide (HPMA) are prototypic and well-characterized polymeric drug carriers that have been broadly implemented in the delivery of anticancer therapeutics.
Ulbrich, K. +8 more
core
National Campaign Against Drug Abuse Social Issues Survey, 1988
Since 1985, as part of the National Campaign Against Drug Abuse, substantial survey research has been undertaken to assess the extent of drug problems, the effectiveness of interventions, and the impact of aspects of the campaign.
Drugs of Dependence Branch, National Drug Abuse Information Centre
core +1 more source
Kansas Prescription Drug and Opioid Advisory Committee and subcommittees and other groups: Diagrams (2 pages) Kansas Prescription Drug and Opioid Advisory Committee.
Kansas Prescription Drug and Opioid Advisory Committee
core +1 more source
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach +9 more
wiley +1 more source
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang +9 more
wiley +1 more source
Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas +16 more
wiley +1 more source
REACTION 2012. 1st International workshop on Real-time and distributed computing in emerging applications.
REACTION 2012
core
Drug use among primary school students, New South Wales, 1986: File p
Comparatively little data has been collected about primary aged students' drug use. This survey has a number of objectives: to monitor the nature and extent of alcohol and other drug use; to provide data from which the need for social policy and ...
NSW Drug and Alcohol Authority
core +1 more source
PANoptosis in the pathogenesis of myelodysplastic syndromes
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla +4 more
wiley +1 more source

